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SUMMARY
Background
There is clear beneﬁt from combination therapy with inﬂiximab and immu-
nosuppressive drugs (IS), but few data are available for adalimumab (ADA).
Aim
Our aim was to assess the efﬁcacy of ADA monotherapy and ADA+IS for
induction and maintenance therapy in Crohn’s disease.
Methods
Retrospective study of patients with Crohn’s disease treated with ADA in
Oxford, UK or Liège, Belgium. Treatment periods were divided into 6-
month semesters. A combination therapy semester was deﬁned as ADA+IS
for at least 3 months; successful induction meant clinical response; a semes-
ter with ﬂare as ADA dose escalation, starting steroids, perianal complica-
tion, or surgery; and ADA failure as ADA withdrawal for secondary loss of
response or intolerance. Semesters with and without ﬂares were compared
through univariate and multivariate analysis.
Results
Successful induction was achieved in 171/207 (83%) patients, with no sig-
niﬁcant difference between ADA+IS and ADA monotherapy (85% vs. 82%,
P = 0.50). Five hundred and sixty-two semesters in 181 patients were
included for maintenance analysis. ADA+IS was not associated with fewer
semesters with ﬂare (34% vs. 35%, P = 0.96), or with ADA failure (6% vs.
8%, P = 0.43). Nevertheless, combination therapy in the ﬁrst semester was
associated with a lower risk of ADA failure (5% vs. 10%, P = 0.04,
OR = 0.48) and combination therapy beyond 6 months was associated with
fewer semesters with ﬂares (14% vs. 36%, P = 0.02, OR = 0.31).
Conclusions
There may be a beneﬁt from ADA+IS combination therapy during the ﬁrst
semester of initiating ADA, with a slight decrease in ADA failure and lower
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The beneﬁt of concommittant oral immunossupressive
drugs with sheduled anti-TNF maintenance therapy has
been established for inﬂiximab (IFX),1 but remains
unclear for adalimumab (ADA), although combination
therapy is routinely used with all anti-TNF agents in
rheumatological practice.2 Concommitant immunosup-
pressive (IS) drugs, including azathioprine (AZA), mer-
captopurine (MP), or methotrexate (MTX), appear to
reduce the risk of antibody formation to the drugs,
which are associated with lower trough levels, shorter
time to relapse and infusion reactions.3, 4 In IS-naive
patients with relatively early Crohn’s disease treated with
IFX, the prospective Study Of biologic and immunomod-
ulator Naive patients In Crohn’s disease (SONIC) trial
clearly demonstrated the beneﬁt of combination therapy
with IFX and AZA.1 In patients with longer duration of
Crohn’s disease, many of whom had already been
exposed to IS in clinical practice, a retrospective study
from Paris also suggested a potential beneﬁt of IFX+IS
combination therapy, at what ever stage IS was com-
bined with IFX.5 Few data are available for ADA. In the
pivotal registration study of ADA (Crohn’s trial of
the fully Human Antibody adalimumab for Remission
Maintenance, CHARM), post-hoc analysis did not detect
any impact of IS co-treatment on the remission rate
achieved at 1 year.6 The Leuven group also reported no
more treatment failure in patients on ADA monothera-
py than combination therapy, but a slightly shorter time
to drug escalation.7 The aim of our study was to assess
the impact of ADA+IS combination therapy on the rate
of response to ADA induction, as well as its effect on
ﬂares of Crohn’s disease or treatment failure during




All patients ever treated with ADA for Crohn’s disease
at the John Radcliffe Hospital, Oxford, UK and CHU
Sart Tilman, Liège, Belgium, were considered for inclu-
sion. The diagnosis of Crohn’s disease was based on
standard criteria,8 with disease distribution and behavior
as most recently assessed at the time of ADA therapy.9
Study design
Retrospective analysis of 6-month treatment periods
(semesters) for induction success and efﬁcacy of mainte-
nance therapy during a minimum 12-month period, for
ﬂare or treatment failure, comparing semesters with and
without combination therapy.
Induction success
For the assessment of response to induction, only
patients with at least 3 months’ exposure to ADA were
considered (Figure 1). Combination therapy for induc-
tion was deﬁned as a patient who had received 3 months
of ADA+IS during the induction period, with IS started
at least 3 months before commencing ADA. Induction
success was evaluated at 3 months, deﬁned as a clinical
response or remission as determined by the gastroenter-
ologist at a routine clinical visit.
Maintenance efﬁcacy
For the assessment of maintenance efﬁcacy, only patients
with at least 12 months’ continuous treatment with
ADA were analysed (Figure 1). The treatment period
was divided into semesters (below). Combination therapy
(ADA+IS) for maintenance was deﬁned as a minimum
3 months’ IS treatment during a semester, with AZA (2–
2.5 mg/kg), MP (1–1.5 mg/kg), or MTX (15–25 mg/week
administrated orally or by injection). Thiopurine therapy
was optimised by weight or leucocyte count, but not by
metabolite monitoring.
Semesters
A semester was deﬁned as a 6-month period with ADA.
A ﬂare semester was deﬁned as deterioration in clinical
symptoms requiring treatment modiﬁcation (ADA rein-
duction, escalation to weekly ADA injection, initiation of
corticosteroids, or switch to another biologic), new peri-
anal complication, or abdominal surgery for active CD.
A remission semester was a semester without a ﬂare on
ADA every other week, or de-escalation from ADA
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weekly to every other week and without a ﬂare during
the 2 following months. A failure semester was deﬁned
as ADA withdrawal for secondary loss of response, or
intolerance. The semester total was the cumulative num-
ber of semesters on treatment. ADA interruption was
deﬁned as interrupted therapy for >4 weeks for any rea-
son (ﬂare, surgery, infection, pregnancy, or cessation
during remission). Re-starting ADA was considered to
be a new treatment period, so more than one treatment
period with ADA was possible for each patient.
Analysis of semesters
Analysis of ﬂare semesters and failure semesters com-
pared semesters on ADA monotherapy and ADA+IS
combination therapy. Each semester was analysed sepa-
rately. Overall analysis excluded the ﬁrst semester and
incomplete semesters, with a separate analysis of the sub-
group of patients exposed to IS during the ﬁrst semester
of ADA therapy, similar to that performed in a previous
study for IFX.5 In the group of patients treated with ADA
+IS during the ﬁrst semester, subpopulations of IS failure
(who had failed IS treatment in the months before start-
ing ADA) and of IS others (meaning those who were
naive to IS, or who started IS at the same time as ADA,
or who for some reason had ADA started without evi-
dence of active disease, such as post-operatively) could be
identiﬁed, so were evaluated separately, as well as a com-
parison between thiopurines (AZA or MP) and MTX.
Statistical analysis
Descriptive statistics are expressed as mean (standard
deviation) for continuous variables and as numbers (per-
centages) for qualitative variables. Induction success was
assessed by comparing proportions achieving clinical
response or remission on ADA monotherapy and ADA
+IS during induction using Chi-square test. Multivariate
logistic regression analysis was performed after univariate
analysis had identiﬁed factors potentially associated with
successful induction.
Maintenance efﬁcacy was assessed by comparing pro-
portions of semesters with ﬂare and failure, for semesters
on ADA monotherapy and ADA+IS in the whole popu-
lation using Chi-squared test.
The risk of ﬂare according to the semester total and
type of IS was studied using generalised estimated equa-
tions.10 Demographic and clinical factors potentially asso-
ciated with a ﬂare semester or failure semester were ﬁrst
analysed using univariate analysis: the factors were age,
gender, weight, age at diagnosis, disease duration, age at
diagnosis according to Montréal classiﬁcation, current
CD location, current CD behaviour, current perineal dis-
ease, previous surgery, number of previous operations,
smoking habit, family history of IBD, spondylarthropathy,
previous use of IFX, ADA, or certolizumab pegol, ADA
induction regimen, CRP at ADA start, ADA+IS and ADA
+IS during the ﬁrst semester, and centre (Oxford/Liège).
Variables with a P-value <0.10 in univariate analysis were
considered for multivariate logistic regression analysis.
A P-value <0.05 was considered signiﬁcant.
The group of patients treated with IS during the ﬁrst
semester of ADA therapy was then analysed using the
same approach. Proportions of subsequent ﬂare semes-
ters on ADA monotherapy and ADA+IS semesters and
factors associated with ﬂare and failure semesters were
studied using univariate and multivariate analysis, using
the same factors as the whole population apart from
ADA+IS during the ﬁrst semester.
The proportion of semesters with ﬂare on ADA+IS
was compared between patients with IS failure and those
with IS tolerant at ADA start using a Chi-squared test.
ADA+thiopurine semesters and ADA+MTX semesters
were also performed using Chi-squared test. Calculations
were performed using the 9.2 version SAS logiciel (SAS
Institute, Cary, NC, USA).
RESULTS
Patient characteristics
A total of 243 patients with IBD (239 Crohn’s disease, 2
ulcerative colitis, 2 IBD unclassiﬁed) exposed to ADA
were screened for inclusion. Those without a deﬁnite
diagnosis of Crohn’s disease, or who did not meet the
criteria of 3 months’ treatment with ADA for assessing
induction success or 12 months’ for maintenance efﬁcacy
were excluded. We identiﬁed 207 patients suitable for
the evaluating induction success (Oxford n = 128, Liege
n = 79) and 181 patients (Oxford n = 98, Liege n = 83)
suitable for evaluating maintenance efﬁcacy (Figure 1).
Among these, 45 had received ADA+IS during the ﬁrst
semester and were further analysed separately. Our retro-
spective analysis identiﬁed only one severe adverse event:
an episode of severe pneumonia requiring intensive care
for 4 days in a patient on ADA monotherapy during the
third semester of ADA treatment. Patient characteristics
are described in Table 1.
Impact of ADA+IS on the response to ADA induction
(n = 207)
The rate of successful ADA induction was 171/207 (83%)
at 3 months. ADA was started with IS in 74 patients
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(36%) and the response to ADA induction did not differ
between the group started on ADA monotherapy and the
group started on ADA+IS (82% and 85% respectively,
p = 0.50). This group included those (n = 47) already on
IS for >3 months at commencement of ADA, subject to
separate analysis. In the multivariate analysis, two inde-




N = 207 (%)
Maintenance study:
Patients treated 12 months
with ADA
N = 181 (%)
Maintenance study:
Patients treated with ADA+IS
during the 1st semester
N = 45 (%)
Age (years, mean ± s.d.) 33 ± 11 33 ± 11 33 ± 13
Male gender 79 (38) 75 (41) 19 (42)
Weight (kg) 67 ± 16 67 ± 14 68 ± 16
Age at diagnosis (years, mean ± s.d.) 22 ± 9 27 ± 8 21 ± 9
Disease duration (years, mean ± s.d.) 11 ± 8 12 ± 10 11 ± 8
Age at diagnosis
A1 44 (21) 44 (24) 14 (31)
A2 154 (74) 131 (73) 29 (65)
A3 9 (5) 6 (3) 2 (4)
Current disease location
L1 24(12) 23 (12) 2 (4)
L2 51 (24) 41 (23) 12 (27)
L3 132 (64) 100 (55) 24 (53)
L4* 23 (11) 19 (10) 7 (15)
Current disease behavior
B1 122 (59) 94 (52) 27 (60)
B2 56 (27) 55 (30) 11 (24)
B3 28 (14) 32 (18) 7 (16)
Active perianal disease 113 (55) 91 (50) 26 (58)
Surgery 68 (34) 90 (50) 15 (33)
Number of surgeries
0 102 (49) 91 (50) 30 (67)
1 64 (31) 51 (28) 6 (13)
2 16 (8) 16 (9) 3 (7)
 3 25 (12) 23 (13) 6 (13)
Smoking habit 68 (34) 66 (38) 15 (36)
Family history of IBD
No 142 (83) 123 (81) 28 (78)
1st degree 13 (8) 11 (7) 2 (5)
 2nd degree 15 (9) 18 (12) 6 (17)
Spondylarthropathy 3 (1) 5 (3) 0 (0)
Previous Inﬂiximab 132 (64) 114 (63) 33 (73)
Previous Adalimumab 25 (12) 18 (10) 3 (7)
Previous Certolizumab 14 (7) 14 (8) 3 (7)
ADA induction regimen
160/80 142 (69) 124 (70) 31 (72)
80/40 20 (10) 20 (11) 6 (14)
none 33 (16) 25 (14) 4 (9)
Unknown 12 (5) 12 (5) 4 (5)
CRP at ADA start (mg/L, mean ± s.d.) 22 ± 31 19 ± 27 15 ± 25
ADA+IS during 1st semester NA* 63 (35) 45 (100)
ADA+IS semesters NA 90 (16) 56 (38)
ADA treatment duration (months, mean ± s.d.) 44 ± 51 26 ± 11 27 ± 11
Severe adverse events 0 (0) 1 (0.5) 1 (2)
Semesters NA 562 147
Centre Oxford/Liège 79/128 (38/62) 98/83 (54/46) 32/13 (71/29)
No patients had isolated L4; all patients with L4 had concomittent L1, L2 or L3 involvement.
* NA, Non applicable.
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pendent factors were associated with failure of ADA
induction: high CRP (44 mg/L vs. 18 mg/L, P = 0.01,
OR = 1.02, 95% CI: 1.01–1.03) and age under 16 at diag-
nosis (P = 0.02, OR = 4.08, 95% CI: 1.49–11.15).
Impact of ADA+IS on maintenance in the whole
population (n = 181)
Five hundred and sixty-two semesters were analyzed,
including 472 semesters on ADA monotherapy and 90
semesters on ADA+IS (thiopurine n = 65, MTX n = 25).
The mean semester total for follow-up was 4 (range: 2–
9).
The rate of semesters with ﬂare in the whole popula-
tion was 35% (n = 195) and no difference was observed
between semesters with ADA monotherapy and semes-
ters with ADA+IS (35% and 34% respectively, P = 0.96)
(Figure 2a). The large majority of semesters with ﬂare
corresponded to the need for escalation to ADA weekly
dosing (n = 157, 81%). We identiﬁed 18 semesters with
surgery (9%), 19 with new perianal complications (10%),
1 with a switch to IFX (0.01%), 12 with ADA reinduc-
tion (7%) and 20 with corticosteroid prescriptions (10%).
No signiﬁcant differences were observed regarding the
need for surgery (P = 0.05) or new perianal complica-
tions (P = 0.21) between ADA monotherapy or ADA+IS
(Table 2). There were no more failures in ADA+IS
semesters compared with ADA monotherapy semesters
(6% and 8% respectively, P = 0.43) in the whole popula-
tion (Figure 3a). The rate of ﬂare semesters was stable
over time (P = 0.90) and did not change according to
ADA±IS (P = 0.08). In multivariate analysis, semesters
with ﬂares were associated with four independent factors:
active perianal disease (P = 0.02, OR = 1.57, 95% CI:
1.07–2.32), previous surgery (P < 0.01, OR = 1.89, 95%
CI: 1.31–2.87), female gender (P = 0.01, OR = 1.68, 95%
CI: 1.12–2.52) and Liège centre (P < 0.01, OR = 1.94,
95% CI: 1.31–2.87). Independent factors associated with
the risk of new perianal complications and abdominal
surgery are shown in Table 3. ADA+IS was not an inde-
pendent parameter associated with ﬂare semester. Con-
cerning ADA failure, the only independent factor
after multivariate analysis was ADA+IS during the ﬁrst
semester (P = 0.04, OR = 0.48, 95% CI: 0.24–0.97). No
(a) (b)
Figure 2 | 5Semesters with ﬂare according to ADA±IS. (a). In the whole population (562 semesters in 181 patients), the
rate of semesters with ﬂare was not statistically different between semesters with ADA monotherapy and ADA+IS
(P = 0.96). (b) In the patients treated with ADA+IS during the ﬁrst semester (147 semesters in 45 patients), ﬂares
were statistically less frequent in semesters with ADA+IS (14%) compared to ADA monotherapy (36%) (P = 0.02).
Table 2 | All CD patients (n = 181): Semesters with IBD
activity according to ADA±IS. The rate of semesters
with ﬂare was not signiﬁcantly different between
patients treated with ADA monotherapy and patients
treated with ADA+IS. Regarding the type of ﬂare,
surgery, new perianal complication or ADA dose
escalation, no difference was demonstrated between
the 2 groups
N (%) ADA monotherapy ADA+IS P-value
IBD ﬂare 164 (35) 31 (34) 0.96
Surgery 12 (7) 6 (19) 0.06
Perianal complications 18 (11) 1 (3) 0.2
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other independent factor, including semester with ADA
+IS, was identiﬁed. The risk of semester with failure was
10% vs. 5% in patients with ADA monotherapy in the
ﬁrst semester and ADA+IS respectively.
Impact of ADA+IS on maintenance in patients
treated during the ﬁrst semester with ADA+IS
(n = 45)
Forty-ﬁve patients received ADA+IS during the ﬁrst
semester and were analysed separately (147 semesters,
including 91 subsequent semesters with ADA monother-
apy and 56 with ADA+IS). Analysis of this subgroup of
patients demonstrated that ﬂares were less frequent in
semesters with continued ADA+IS compared with
semesters with ADA monotherapy (14% and 36%
respectively, P = 0.02, OR = 0.31, 95% CI: 0.12–0.81)
(Figure 2b). The rate of ﬂare did not change over time
(P = 0.86) and the protective effect of ADA+IS was sta-
ble according to the semester total (P < 0.01) (Figure 4).
Flare semester characteristics were as followed: ADA
weekly (n = 35/41, 86%), abdominal surgery (n = 3,
7%), perianal complications (n = 3, 7%), corticosteroids
(n = 22%). There were no more semesters with ADA
failures in semesters with ADA+IS compared with
semesters with ADA monotherapy (2% and 4% respec-
tively, P = 0.41) (Figure 3b). Among those patients on IS
at initiation of ADA, the proportion of semesters with
ﬂare did not differ between patient having failed IS or
not before ADA start (P = 0.86). Futhermore, there was
no signiﬁcant difference between semesters with ADA
+thiopurine and ADA+MTX (P = 0.84).
In multivariate analysis, three independent factors
were signiﬁcantly associated with ﬂare semesters: ADA
monotherapy (P = 0.02, OR = 3.28, 95% CI: 1.25–8.3),
previous surgery (P = 0.01, OR = 3.69, 95% CI: 157–
8.68) and Liège centre (P = 0.01, OR = 3.17, 95% CI:
1.40–7.19). Factors speciﬁcally associated with the risk of
new perianal complications and abdominal surgery were
not analysed because of the small number of events in
this subgroup. No clinical or demographic factors were
associated with ADA failure.
DISCUSSION
Although the beneﬁt of IS in patients treated with IFX
has been clearly demonstrated both in IS naïve and IS
(a) (b)
Figure 3 | 6Semesters with ADA failure according to ADA±IS. In the whole population (a) (562 semesters in 181
patients) and in the patients treated with ADA+IS during the ﬁrst semester (b) (147 semesters in 45 patients), the
rate of semesters with ADA failure was not statistically different between semesters with ADA monotherapy and
ADA+IS (P = 0.4).
Table 3 | Independant risk factors for surgery and




Surgery (n = 18)
Male gender <0.01 13.16 (3.29–52.63)
Disease duration 0.01 1.12 (1.01–1.21)
Active perianal disease 0.02 5.51 (1.30–23.15)
Oxford centre <0.01 8.8 (2.29–34.24)
Perianal ﬂare (n = 19)
Active perianal disease 0.01 7.74 (1.65–36.22)
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exposed patients, the beneﬁt of such combination ther-
apy is not well documented with ADA. In this retrospec-
tive analysis, we could not show any beneﬁt of ADA+IS
for achieving induction success for clinical response and
remission. In maintenance ADA therapy, we could also
not show any decrease in semesters with ﬂares during
semesters with ADA+IS combination therapy. This is
consistent with the results of the subanalysis of the
CHARM trial,6 but at odds with the practice-based
French study on IFX.5
Nevertheless, there was a beneﬁt of combination ther-
apy (ADA+IS) when IS had been given during the ﬁrst
semester of ADA treatment. This was associated with
half the rate of ADA failure over the subsequent semes-
ters. Although this was quantatively small (from 10% to
5%), it is likely to be clinically as well as statistically sig-
niﬁcant. Furthermore, among these patients treated dur-
ing the ﬁrst semester with ADA+IS, there were fewer
semesters with ﬂares during subsequent maintenance
treatment with ADA+IS compared with semesters on
ADA monotherapy, suggesting a sustained beneﬁt.
The large majority of semester ﬂares were character-
ised by escalation in ADA dosage. On subanalysis, it was
only prevention of dose escalation with ADA that bene-
ﬁted from continued ADA+IS combination therapy after
having been treated by this combination in the ﬁrst
semester, not other deﬁnitions of ﬂares, including new
perianal complications or abdominal surgery, although
numbers (19 and 18/195 semesters with abdominal oper-
ations and new perianal complications respectively) in
the latter groups were very small. A similar beneﬁt of
ADA+IS was suspected by the Leuven group who noted
a shorter time to ADA dose escalation, but no excess of
treatment failure on ADA monotherapy.7
Combination therapy with IS can reduce anti-TNF
antibody formation and improve the pharmacokinetics
of anti-TNF drugs.11, 12 It has also been demonstrated
that discontinuation of ADA due to treatment failure is
associated with low ADA trough level concentrations.7
In our study, the beneﬁt of combination therapy at the
time of starting ADA, whether or not continued after
the ﬁrst semester, might be explained by early inhibition
of anti-ADA antibody formation, leading to higher
trough levels from the start of the therapy that could
predict long-term efﬁcacy of ADA. An alternative expla-
nation might simply be better control of the inﬂamma-
tion on combination therapy from the onset of
treatment that reduces the risk of relapse compared with
ADA monotherapy. Prospective studies combined with
anti-ADA antibody and ADA trough level measurements
are required to validate these hypotheses.
Apart from combination therapy in the ﬁrst semester,
among the factors associated with ﬂare semesters, were
previous surgery and being treated in Liège. Although
previous abdominal surgery is consistent with more
severe disease,11 the association with Liège deserves a
speciﬁc comment. In the current study, fewer in the Bel-
gian cohort received IS than the British cohort, but
weekly treatment with ADA was more common in Bel-
gium. As the commonest reason for deﬁning a ﬂare was
dose escalation on monotherapy, this treatment strategy
is reﬂected in the increased rate of ﬂares in Liège com-
pared to Oxford. In contrast, surgery and perianal com-
plications were more frequent in Oxford, but accounted
for only a small proportion of ﬂares. These results may
reﬂect easier access to anti-TNF therapy in Belgium.
Indeed, the Belgian healthcare system allows easier access
to long-term anti-TNF therapy as well as dose escalation,
whereas the British healthcare system encourages
shorter treatment duration with a higher threshold for
dose escalation. This might explain why, in similar clini-
cal circumstances, patients may be treated in Belgium
with weekly ADA monotherapy, but in the UK with
ADA every other week in combination with IS or even
surgery.
Our study was closely modelled on that of Sokol
et al.,5 who demonstrated a beneﬁt of IS+IFX compared
with IFX monotherapy using semester-based analysis.
However, in their study, only patients receiving IFX+IS
Figure 4 | 7Semesters with ﬂare according to ADA±IS
and semesters total in the patients treated with ADA
+IS during the ﬁrst semester (147 semesters in 45
patients). The rate of semesters with ﬂare was stable
over the time (P = 0.86). The protective effect of ADA
+IS compared to ADA monotherapy for a ﬂare
semester did not change according to the semester
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during the ﬁrst semester were included, which corre-
sponds to our subgroup of 45 patients (157 semesters)
treated with ADA+IS during the ﬁrst semester. In their
study, IFX+IS was associated with fewer semesters with
dose escalation or interval reduction compared with sub-
sequent semesters on IFX monotherapy. In this respect,
we conﬁrm a similar result in those on ADA+IS during
the ﬁrst semester, with fewer needing ADA dose escala-
tion in subsequent ADA+IS semesters compared with
ADA monotherapy. The Sokol study5 also reported fewer
perianal complications or switches in biological therapy
in IFX+IS semesters, but no impact on the frequency of
semesters with abdominal surgery. These events were too
rare to analyse in our population. Furthermore, 70% of
our patients had already been treated by another anti-
TNF agent (usually IFX) before ADA; hence, switch bio-
logical therapy in the Sokol study might be compared
with ADA failure in our study. Although Sokol et al.5
found a modest decrease in the need to switch to
another biologic during IFX+IS semesters, we found no
beneﬁt of prolonged ADA+IS beyond the ﬁrst semester.
This is more comparable to the results in the Leuven
cohort and IMID trial.12
Our study has several limitations due mainly to its
retrospective nature. First, the deﬁnition of the ﬂare was
retrospective and included different clinical situations (e.
g. starting steroids, dose escalation, surgery, etc.). Second,
patients were not randomised between ADA monothera-
py and ADA+IS, hence these two populations are not
strictly comparable. Third, there were no serum samples
to measure trough levels or anti-ADA antibodies. Fourth,
data on the intake and the dose of corticosteroid during
the induction time with ADA were missing for half of
the patients, although just 5% of all data in the induction
group were missing. Although the available data did not
show any inﬂuence of corticosteroids on the response to
ADA induction, an effect cannot be excluded; hence, a
lack of inﬂuence of steroids on response to ADA cannot
be concluded. Nevertheless, in this retrospective analysis
from the experience of two referral centers, q the beneﬁt
of ADA+IS appears limited to those co-treated at the
start of ADA therapy. Combination therapy with ADA
during the ﬁrst semester slightly decreased the rate of
ADA failure during maintenance therapy independently
of whether ADA+IS was continued beyond the ﬁrst
semester. During maintenance therapy, ADA+IS was
associated with a lower rate of ADA dose escalation.
We think our results may help clinicians decide
whether to use ADA in monotherapy or combination
therapy, particularly, with regard to the potential beneﬁts
from such combination at the start of ADA. Accordingly,
it seems reasonable to start with the combination and
then continue ADA monotherapy after about 6 months
of combination therapy, as the need for dose escalation
does not appear to be affected after the ﬁrst semester.
The choice of the treatment strategy needs to be bal-
anced with potential risks of infection and cancer and
also with the cost of the strategy. In older patients with
high comorbidity, or younger male subjects at increased
risk of hepatosplenic T-cell lymphoma14 on combination
therapy, stopping the IS 6 months after ADA start seems
a reasonable option. It is also not unreasonable to give
ADA as monotherapy from the start as long as the slight
increase in the absolute risk of treatment failure is recog-
nised. A randomised trial is needed to conﬁrm whether
ADA+IS is more effective than ADA monotherapy, par-
ticularly to examine whether any beneﬁt is limited to
combination therapy in the ﬁrst semester, and whether it
simply decreases the need for ADA dose escalation, or
whether it also decreases clinically relevant measures of
patient outcome.
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